Τίτλος:
The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A
Multicentre Analysis of Real-life Clinical Data
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Literature regarding the effect of biologics on the course of mycosis
fungoides (MF) is scarce. This multi-centre study analysed retrospective
data on 19 patients with MF, who were treated with biologics; 12 for
inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as
an inflammatory skin disease. Eight patients were treated with
anti-tumour necrosis factor-alpha-monotherapy; 6 had early-stage MF, in
3 patients MF preceded and in 3 MF was diagnosed after initiation of
biologics, with no stage-progression or with stable disease,
respectively (median treatment time concurrent with MF 57 months). Two
patients had advanced stage MF: IIB, treated for 15 months with no
stage-progression, and IVA1, treated for 8 months, died of disease 10
months later. The other 11/19 patients received anti-interleukin-17A
and/or anti-interleukin-12/23 or anti-interleukin-23 (with/without
anti-tumour necrosis factor-alpha/anti-interleukin-4/13), with
stage-progression in 8 patients after a median of 8 months' treatment.
Although, in general, biologics should be avoided in patients with MF,
these results indicate that anti-tumour necrosis
factor-alpha-monotherapy might not aggravate the disease course in
early-stage patients. Interleukin-17A, interleukin-12/23 and
interleukin-23 pathway-blockers may prompt progression of MF.
Συγγραφείς:
Amitay-Laish, Iris
Guenova, Emmanuella
Ortiz-Romero, Pablo L.
and Vico-Alonso, Cristina
Rozati, Sima
Geskin, Larisa J. and
Nikolaou, Vasiliki
Papadavid, Evangelia
Barzilai, Aviv and
Pavlovsky, Lev
Didkovsky, Elena
Prag Naveh, Hadas
Akilov,
Oleg E.
Hodak, Emmilia
Περιοδικό:
Acta Dermato-Venereologica
Εκδότης:
Acta Dermato-Venereologica
Λέξεις-κλειδιά:
cutaneous T cell lymphoma; mycosis fungoides; biologic treatment;
anti-TNF alpha; anti-IL-12/23; anti-IL23; anti-IL17A
DOI:
10.2340/00015555-3642
